Clinical Assessment Software Application |
CASA |
Clinical Trial: Quality of Life of Adult Cancer Survivors Who Have Undergone a Previous Bone Marrow or Peripheral Stem Cell Transplant for a Childhood Hematologic Cancer
This study is currently recruiting patients.
Verified by National Cancer Institute (NCI) July 2005
Purpose
RATIONALE: Studying quality of life in cancer survivors may help determine the long-term effects of hematologic cancer and may help improve the quality of life for future cancer survivors.
PURPOSE: This clinical trial is studying the quality of life of adult cancer survivors who have undergone a previous bone marrow or peripheral stem cell transplant for a childhood hematologic cancer.
| Condition | Intervention | Phase |
|---|---|---|
| childhood Hodgkin''''s lymphoma childhood non-Hodgkin''''s lymphoma Leukemia Quality of Life | Procedure: cognitive assessment Procedure: complications of therapy assessment/management Procedure: psychosocial assessment/care Procedure: quality-of-life assessment Procedure: supportive care/therapy | Phase II |
MedlinePlus related topics: Hodgkin''''s Disease; Leukemia, Adult Acute; Leukemia, Adult Chronic; Leukemia, Childhood; Lymphoma
Study Type: Interventional
Study Design: Treatment
Official Title: Phase II Study of Quality of Life of Adult Cancer Survivors Who Have Undergone Prior Bone Marrow or Peripheral Blood Stem Cell Transplantation for a Pediatric Hematologic Malignancy
OBJECTIVES:
- Determine the extent to which adult cancer survivors who have undergone prior bone marrow or peripheral blood stem cell transplantation for a pediatric hematologic malignancy require ongoing health care and whether these needs change with increasing time after transplantation.
- Correlate physical capabilities, body image, physical limitations, including sexuality issues which alter or influence lifestyle, with time after transplantation in these patients.
- Determine whether cognitive abilities relative to memory and neurobehavioral ratings change with increasing time after transplantation in these patients.
- Correlate social and relationship abilities with length of time after transplantation in these patients.
OUTLINE: Patients and siblings complete a self-report quality of life questionnaire, including outcome assessments of neuroendocrine function, cognitive abilities, physical capability, and psychosocial behavior.
PROJECTED ACCRUAL: Approximately 750 patients (375 adult cancer survivors [case group] and 375 siblings [control group]) will be accrued for this study within 7 years.
Eligibility
DISEASE CHARACTERISTICS:
- Case group
- Previously treated with an allogeneic, unrelated, syngeneic, or autologous bone marrow or peripheral blood stem cell transplantation for a hematologic malignancy ≥ 5 years ago while enrolled on 1 of the following protocols:
- FHCRC-179.07T
- FHCRC-446.03T
- FHCRC-661.04
- FHCRC-697.00
- FHCRC-796.00
- FHCRC-843.00
- Disease-free survivor
- Under 18 years of age at time of transplantation
- Any prior preparative regimen allowed
- Control group
- Sex-matched sibling within 5 years of patient''''s age*
- No chronic illnesses (e.g., cancer, diabetes, or asthma) that require medication
- No allergies that limit physical activity NOTE: *If such a sibling is not available, but another sibling is available, then that sibling would be asked to nominate a friend or relative of the same gender as the patient who is also within 5 years of the patient''''s age; the patient must consent in order for the control subject to participate
PATIENT CHARACTERISTICS:
Age
- See Disease Characteristics
- 18 and over
Performance status
- Not specified
Life expectancy
- Not specified
Hematopoietic
- Not specified
Hepatic
- Not specified
Renal
- Not specified
Other
- Must be able to speak, read, and write English
PRIOR CONCURRENT THERAPY:
Biologic therapy
- See Disease Characteristics
Chemotherapy
- Not specified
Endocrine therapy
- Not specified
Radiotherapy
- Not specified
Surgery
- Not specified
Location and Contact Information
Washington
Fred Hutchinson Cancer Research Center, Seattle, Washington, 98109-1024, United States; Recruiting
Jean E. Sanders, MD, Principal Investigator, Fred Hutchinson Cancer Research Center
More Information
Clinical trial summary from the National Cancer Institute''''s PDQ® database
Last Updated: August 9, 2005
Record first received: August 2, 2005
ClinicalTrials.gov Identifier: NCT00126477
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-08-23

Not Signed In -


